17029-Fallopian Tube Cancer-NA-1278

Fallopian Tube Cancer

FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator’s Choice of Chemotherapy in Women with Folate Receptor alpha-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer (0403)

  • Details

ClinicalTrials.gov ID: NCT02631876
Diagnosis Type: NA
USOR Number: 17029

  • Address

19646 N 27th Avenue, Suite 406
Phoenix, AZ 85027
P: (602) 357-2400

Find a Clinical Trial

Use the abbreviation for your state (ie. FL, TX, NV)
Search by practice name, trial titles, indicators and specific disease types.